Dr. Levine on Evolving Treatment Options for Patients With mCRPC

Richard M. Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer (mCRPC).

There are many different options now for patients diagnosed with metastatic prostate cancer, Levine explains, with most of them being associated with minimal side effects. The mainstay of treatment for prostate cancer is androgen-deprivation therapy, with leuprolide acetate for depot suspension (Lupron Depot) or leuprolide acetate for injectable suspension (Eligard), or degarelix (Firmagon). Patients can also receive bicalutamide (Casodex). These types of agents have demonstrated encouraging response rates and can also relieve pain and improve quality of life.

Patients with prostate cancer that is metastatic to the bone often benefit from zoledronic acid (Zometa), denosumab (Xgeva), or pamidronic acid (Aredia). Additional agents include the immune therapy sipuleucel-T (Provenge), radiation therapy for diffuse bone pain, abiraterone acetate (Zytiga), and enzalutamide (Xtandi).